



CNO Financial Group, Inc. (CNO)

Updated October 31st, 2024, by Kody Kester

Key Metrics

Current Price:	\$35	5 Year CAGR Estimate:	11.6%	Market Cap:	\$3.6B
Fair Value Price:	\$38	5 Year Growth Estimate:	8.0%	Ex-Dividend Date¹:	12/05/24
% Fair Value:	93%	5 Year Valuation Multiple Estimate:	1.5%	Dividend Payment Date:	12/20/24
Dividend Yield:	1.8%	5 Year Price Target	\$55	Years Of Dividend Growth:	12
Dividend Risk Score:	C	Retirement Suitability Score:	D	Rating:	Buy

Overview & Current Events

CNO Financial Group, Inc. serves middle-income pre-retirees and retired Americans. The company's offerings include Medicare supplement insurance, long-term care insurance, annuities, and individual life insurance. Founded in 1979, CNO is well-established within its industry. Bankers Life, Washington National, and Colonial Penn are among the company's most recognized brand names. As of September 30th, the company served 3.2 million customers with its insurance policies and annuities and had \$38 billion in total assets.

The company serves consumers through the Consumer and Worksite Divisions. As it sounds, the Consumer Division serves the needs of individual consumers via the phone, online, virtually, face-to-face with agent interaction, or some mix of these modes. The Worksite Division sells life and health insurance products in the workplace to businesses, associations, and other membership groups, serving consumers at their place of employment and virtually.

In 2023, premiums from annuities accounted for \$1.6 billion of CNO's total premiums collected (39%). Supplemental health premiums million made up ~\$707 million in total premiums collected for the year (17%). Medicare supplement plans chipped in another ~\$609 million or 15% of total collected premiums. Long-term care plans collected another ~\$262 million in premiums or 6% of total collected premiums. Finally, life insurance plans made up the remaining \$937 million of premiums or 23% of total collected premiums.

On October 31st, CNO released its financial results for the third quarter ended September 30th. The company's total revenue surged 19.2% over the year-ago period to more than \$1.1 billion during the quarter. Annuity collected premiums climbed 25% higher to a record high in the quarter. A 26% uptick in Medicare Advantage sales also contributed to this topline growth. CNO's operating EPS rose by 25% year-over-year to \$1.10 for the quarter. The company's non-GAAP net profit margin contracted just 14 basis points to 10.6% during the quarter. That was more than offset by a 6.4% drop in CNO's diluted share count, which is how operating EPS growth outpaced total revenue growth in the quarter.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$1.19	\$1.41	\$1.47	\$1.75	\$1.83	\$1.85	\$2.53	\$2.79	\$2.33	\$3.09	\$3.45	\$5.07
DPS	\$0.24	\$0.27	\$0.31	\$0.35	\$0.39	\$0.43	\$0.47	\$0.51	\$0.55	\$0.59	\$0.64	\$0.84
Shares²	203.3	184.0	173.8	166.9	162.2	148.1	135.3	120.4	114.3	109.4	103.9	73.1

Thanks to its solid operating results, the consensus for 2024 diluted EPS is much higher. This has led us to reduce our annual growth forecast to 8%. CNO's expansion into additional geographies and a higher agent count should continue to keep total revenue moving upward. CNO's significant cash flow should also support substantial share repurchases in the years ahead. These elements arguably provide a reasonable path for the company to meet our updated growth expectations.

¹ Estimate

² Share count is in millions.



CNO Financial Group, Inc. (CNO)

Updated October 31st, 2024, by Kody Kester

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Avg. P/E	14.3	13.5	13.0	14.1	8.1	9.7	8.8	8.5	9.8	9.0	10.1	10.9
Avg. Yld.	1.4%	1.4%	1.6%	1.4%	2.6%	2.4%	2.1%	2.1%	2.4%	2.1%	1.8%	1.5%

Since 2014, CNO's P/E ratio has ranged from as low as the high-single-digits to the low teens. The average P/E ratio of 10.9 is well within this range. Considering that CNO's annual diluted EPS growth potential is holding up, we believe a multiple of 10.9 remains realistic. The stock's current P/E ratio of 10.1 is below our estimated fair value and offers a reasonable margin of safety.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	20%	19%	21%	20%	21%	23%	19%	18%	24%	19%	19%	17%

CNO's trusted reputation and nationally recognized brands allow it to effectively compete against larger industry peers. That's how the company continues to grow its consumer base, revenue, and profits.


CNO's balance sheet is also a strength. The company's major brands all boast A-rated balance sheets on stable outlooks from the four major credit rating agencies (AM Best, S&P, Fitch, and Moody's). CNO itself possesses BBB+, BBB-, Baa3 (BBB- equivalent), and BBB credit ratings from Fitch, S&P, Moody's, and AM Best, respectively.

These investment-grade credit ratings are backed up by a total consolidated risk-based capital ratio or RBC ratio of 388% as of September 30th. This is better than the 375% RBC ratio that the company targets. As of September 30th, CNO's \$453 million in holding company liquidity was triple the target minimum holding company liquidity amount of \$150 million. Finally, the company's dividend payout ratio in the high-teens range also somewhat shields the company from a downturn in profits.

Final Thoughts & Recommendation

CNO's 1.8% dividend yield, 8.0% annual diluted EPS growth prospects, and 1.5% annual valuation multiple upside could position it for 11.6% annual total returns over the medium term. As a result, we're reiterating our buy rating.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



CNO Financial Group, Inc. (CNO)

Updated October 31st, 2024, by Kody Kester

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	4,145	3,801	3,992	4,302	4,314	4,016	3,821	4,122	3,577	4,147
SG&A Exp.	242	205	231	237	233	238	253	268	288	291
D&A Exp.	274	283	275	265	292	268	304	237	249	267
Net Profit	51	271	358	176	(315)	409	302	570	631	277
Net Margin	1.2%	7.1%	9.0%	4.1%	-7.3%	10.2%	7.9%	13.8%	17.6%	6.7%
Free Cash Flow	122	748	776	633	318	697	736	598	495	583
Income Tax	124	97	(5)	305	50	(135)	43	163	186	80

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	31156	31125	31975	33110	31440	33631	35340	36204	33133	35103
Cash & Equivalents	68	364	189	179	62	75	54	100	69	115
Accounts Receivable	2991	2859	2260	2175	4925	4786	4584	4354	4223	4041
Total Liabilities	26468	26987	27488	28263	28069	28954	29856	30945	31364	32887
Long-Term Debt	3571	4136	4223	3972	3980	3786	3931	4001	3883	4151
Shareholder's Equity	4688	4139	4487	4848	3371	4677	5484	5260	1769	2216
LTD/E Ratio	0.76	1.00	0.94	0.82	1.18	0.81	0.72	0.76	2.20	1.87

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	0.2%	0.9%	1.1%	0.5%	-1.0%	1.3%	0.9%	1.6%	1.8%	0.8%
Return on Equity	1.1%	6.1%	8.3%	3.8%	-7.7%	10.2%	5.9%	10.6%	17.9%	13.9%
ROIC	0.6%	3.3%	4.2%	2.0%	-3.9%	5.2%	3.4%	6.1%	8.5%	4.6%
Shares Out.	203.3	184.0	173.8	166.9	162.2	148.1	135.3	120.4	114.3	109.4
Revenue/Share	19.04	19.47	22.39	24.99	26.07	25.55	26.69	31.44	30.38	36.02
FCF/Share	0.56	3.83	4.35	3.68	1.92	4.43	5.14	4.56	4.21	5.06

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.